Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US10988436 | ORPHALAN | Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use |
May, 2039
(15 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11072577 | ORPHALAN | Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use |
May, 2039
(15 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product (NP) | Apr 28, 2025 |
Orphan Drug Exclusivity (ODE) | Apr 28, 2029 |
Drugs and Companies using TRIENTINE TETRAHYDROCHLORIDE ingredient
Market Authorisation Date: 28 April, 2022
Treatment: A method for the treatment of adult patients with stable wilson’s disease who are de-coppered and tolerant to penicillamine
Dosage: TABLET;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic